Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a vitamin B3 tablet help restore energy in long COVID?

NCT ID NCT07798570

Symptom relief Sponsor: University Hospital Schleswig-Holstein Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This study tests whether a special vitamin B3 tablet, called CICR-NAM, can help people with post-COVID syndrome. The tablet releases nicotinamide in the lower intestine to support energy metabolism. Researchers will give one 500 mg tablet daily for up to 4 months to 100 adults with post-COVID syndrome and low tryptophan levels. They will measure changes in blood tryptophan levels over time to see if the supplement helps.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CICR-NAM, a special form of vitamin B3 (nicotinamide) that releases the vitamin in the lower intestine
What this could lead to
If it works, this could point toward a simple, well-tolerated supplement to help people with post-COVID syndrome recover energy and physical performance.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. The supplement may not improve symptoms for everyone, and results may not apply beyond this specific clinic setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * all sexes; * minimum age 18 years; no upper age limit; * post-COVID syndrome (PCS) * serum tryptophan \<55 µmol/L (UKSH reference range: 48-109 µmol/L); * participation in the therapy groups of the PCS outpatient clinic at UKSH Campus Kiel. Exclusion Criteria: * Known allergies or intolerances to any component of CICR-NAM; * inability to provide informed consent; * pregnancy or breastfeeding; * severe comorbid disease (especially renal insufficiency, uncontrolled autoimmune diseases, liver disease, or malignancy); * long-term use of higher doses of medications that raise gastric pH (for example proton pump inhibitors, H2 receptor antagonists, or antacids), as an increase in pH toward approximately 7 may cause premature release of nicotinamide from CICR-NAM; * use of supplements containing more than 20 mg nicotinamide, nicotinamide riboside, nicotinamide mononucleotide, nicotinic acid, or NAD+ per daily dose.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post COVID syndrome long COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post COVID syndrome long COVID

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.